SAN
DIEGO, Oct. 29, 2024 /PRNewswire/ -- Heron
Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a
commercial-stage biotechnology company, today announced that the
Company will host a conference call and live webcast on
Tuesday, November 12, 2024, at
8:00 a.m. ET to report third quarter
2024 financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the
following registration link which will provide participants
with dial-in details. To avoid delays, we encourage participants to
dial into the conference call fifteen minutes ahead of the
scheduled start time. The conference call will also be available
via webcast under the Investor Relations section of Heron's website
at www.herontx.com. An archive of the teleconference and webcast
will also be made available on Heron's website for 60 days
following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage
biotechnology company focused on improving the lives of patients by
developing and commercializing therapeutic innovations that improve
medical care. Our advanced science, patented technologies, and
innovative approach to drug discovery and development have allowed
us to create and commercialize a portfolio of products that aim to
advance the standard-of-care for acute care and oncology patients.
For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management's expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, but are not limited to, risks and
uncertainties identified in the Company's filings with
the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and
Heron takes no obligation to update or revise these statements
except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download
multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-third-quarter-2024-financial-results-on-tuesday-november-12-2024-302290555.html
SOURCE Heron Therapeutics, Inc.